title: Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06.
abstract: OBJECTIVE
  The primary aim of this study was to compare the relative efficacy of oral uracil and tegafur (UFT) plus leucovorin (LV) with the efficacy of weekly intravenous fluorouracil (FU) plus LV in prolonging disease-free survival (DFS) and overall survival (OS) after primary surgery for colon carcinoma.
  
  
  METHODS
  Between February 1997 and March 1999, 1,608 patients with stage II and III carcinoma of the colon were randomly assigned to receive either oral UFT+LV or intravenous FU+LV.
  
  
  RESULTS
  Of the total patients, 47% had stage II colon cancer, and 53% had stage III colon cancer. Median follow-up time was 62.3 months. The estimated hazard ratio (HR) for OS of patients who received UFT+LV versus that of patients who received FU+LV was 1.014 (95% CI, 0.825 to 1.246). The estimated HR for DFS was 1.004 (95% CI, 0.847 to 1.190). Cox proportional hazards model analyses with regard to age (< 60 v > or = 60 years), stage, or number of involved nodes (none v one to three v > or = four nodes) revealed no interaction with OS or DFS. Toxicity was similar in the two groups. In the UFT+LV arm, 38.2% of patients experienced any grade 3 or 4 toxic event compared with 37.8% of patients in the FU+LV arm. Primary quality-of-life end points did not differ between the two regimens, although convenience of care analysis favored UFT+LV.
  
  
  CONCLUSIONS
  UFT+LV achieved similar DFS and OS when compared with an intravenous, weekly, bolus FU+LV regimen. The two regimens were equitoxic and generally well tolerated.
authors.affiliation: National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212, USA.
authors.forename: Barry C
authors.initials: BC
authors.lastname: Lembersky
authors.forename: H Samuel
authors.initials: HS
authors.lastname: Wieand
authors.forename: Nicholas J
authors.initials: NJ
authors.lastname: Petrelli
authors.forename: Michael J
authors.initials: MJ
authors.lastname: O'Connell
authors.forename: Linda H
authors.initials: LH
authors.lastname: Colangelo
authors.forename: Roy E
authors.initials: RE
authors.lastname: Smith
authors.forename: Thomas E
authors.initials: TE
authors.lastname: Seay
authors.forename: Jeffrey K
authors.initials: JK
authors.lastname: Giguere
authors.forename: M Ernest
authors.initials: ME
authors.lastname: Marshall
authors.forename: Andrew D
authors.initials: AD
authors.lastname: Jacobs
authors.forename: Lauren K
authors.initials: LK
authors.lastname: Colman
authors.forename: Atilla
authors.initials: A
authors.lastname: Soran
authors.forename: Greg
authors.initials: G
authors.lastname: Yothers
authors.forename: Norman
authors.initials: N
authors.lastname: Wolmark
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D016609:Neoplasms, Second Primary / Q000209:etiology; D011788:Quality of Life; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects; D014498:Uracil / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D005641:Tegafur; D014498:Uracil; D002955:Leucovorin; D005472:Fluorouracil